1.
Ann Neurol
; 90(2): 315-318, 2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34114269
RESUMO
Although SARS-CoV-2 vaccines are very safe, we report 4 cases of the bifacial weakness with paresthesias variant of Guillain-Barré syndrome (GBS) occurring within 3 weeks of vaccination with the Oxford-AstraZeneca SARS-CoV-2 vaccine. This rare neurological syndrome has previously been reported in association with SARS-CoV-2 infection itself. Our cases were given either intravenous immunoglobulin, oral steroids, or no treatment. We suggest vigilance for cases of bifacial weakness with paresthesias variant GBS following vaccination for SARS-CoV-2 and that postvaccination surveillance programs ensure robust data capture of this outcome, to assess for causality. ANN NEUROL 2021;90:315-318.
Assuntos
Vacinas contra COVID-19/efeitos adversos , Síndrome de Guillain-Barré/induzido quimicamente , Síndrome de Guillain-Barré/diagnóstico , Vacinas contra COVID-19/administração & dosagem , Glucocorticoides/administração & dosagem , Síndrome de Guillain-Barré/tratamento farmacológico , Humanos , Imunoglobulinas Intravenosas/administração & dosagem , Masculino , Pessoa de Meia-Idade , Prednisolona/administração & dosagem , Vacinação/efeitos adversos , Adulto Jovem
2.
J Neuroophthalmol
; 43(4): e356, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35051982
3.
Neurology
; 100(11): 542-543, 2023 03 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36914275